CL2015000699A1 - Métodos para tratamiento de cáncer. - Google Patents
Métodos para tratamiento de cáncer.Info
- Publication number
- CL2015000699A1 CL2015000699A1 CL2015000699A CL2015000699A CL2015000699A1 CL 2015000699 A1 CL2015000699 A1 CL 2015000699A1 CL 2015000699 A CL2015000699 A CL 2015000699A CL 2015000699 A CL2015000699 A CL 2015000699A CL 2015000699 A1 CL2015000699 A1 CL 2015000699A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- cancer treatment
- administer
- treat cancer
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/34—Free of silicones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
METODO PARA TRATAR CANCER QUE COMPRENDE ADMINISTRAR POR VIA INTRATUMORAL UN AGENTE TERAPEUTICO Y UN AGENTE MEJORADOR DE LA PERMEACION INTRACELULAR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261703890P | 2012-09-21 | 2012-09-21 | |
US201261707733P | 2012-09-28 | 2012-09-28 | |
US201361779509P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015000699A1 true CL2015000699A1 (es) | 2015-11-27 |
Family
ID=50341876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015000699A CL2015000699A1 (es) | 2012-09-21 | 2015-03-19 | Métodos para tratamiento de cáncer. |
Country Status (19)
Country | Link |
---|---|
US (5) | US9351997B2 (es) |
EP (1) | EP2897620B1 (es) |
JP (2) | JP6374388B2 (es) |
KR (1) | KR101839864B1 (es) |
CN (1) | CN104884065B (es) |
AU (2) | AU2013318338B2 (es) |
BR (1) | BR112015006176B1 (es) |
CA (1) | CA2884707C (es) |
CL (1) | CL2015000699A1 (es) |
CY (1) | CY1123258T1 (es) |
DK (1) | DK2897620T3 (es) |
ES (1) | ES2813340T3 (es) |
IL (1) | IL237791B (es) |
MX (1) | MX2015003643A (es) |
PL (1) | PL2897620T3 (es) |
PT (1) | PT2897620T (es) |
RU (1) | RU2657749C2 (es) |
SG (2) | SG10202011046RA (es) |
WO (1) | WO2014046983A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2897620T3 (da) | 2012-09-21 | 2020-08-17 | Intensity Therapeutics Inc | Fremgangsmåde til behandling af cancer |
CA2889530A1 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
EP3003316B1 (en) * | 2013-05-31 | 2020-07-22 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
EP3085380B1 (en) | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
WO2016062290A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途 |
US20160166679A1 (en) * | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN105983097B (zh) * | 2015-01-28 | 2021-06-08 | 华中科技大学同济医学院附属协和医院 | 一种抗肿瘤制剂及其制备方法 |
CN107405380B (zh) * | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
WO2016144976A1 (en) * | 2015-03-09 | 2016-09-15 | Kings College London | Combination therapy with rar alpha agonists for enhancing th1 response |
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
KR102551708B1 (ko) | 2015-06-04 | 2023-07-06 | 크리티테크, 인크. | 수집 장치 및 사용 방법 |
PL3310379T3 (pl) * | 2015-06-18 | 2020-03-31 | Vaximm Ag | Szczepionka dna wycelowana w vegfr-2 do terapii skojarzonej |
WO2017003267A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
BR112018001292A2 (pt) | 2015-07-24 | 2018-09-11 | Kimberly Clark Co | métodos para melhor liberação de agentes ativos a tumores |
CN105241872B (zh) * | 2015-09-01 | 2018-09-25 | 中国科学院深圳先进技术研究院 | 检测血液中半乳凝集素-1的方法及所用试剂 |
TWI733719B (zh) * | 2015-12-07 | 2021-07-21 | 美商河谷控股Ip有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
JP6994240B2 (ja) * | 2015-12-07 | 2022-02-04 | 国立大学法人京都大学 | Pd-1シグナル阻害剤の併用療法 |
KR20230017354A (ko) | 2016-04-04 | 2023-02-03 | 크리티테크, 인크. | 고형 종양의 치료 방법 |
JP7114481B2 (ja) | 2016-04-07 | 2022-08-08 | ジェムバックス アンド カエル カンパニー,リミティド | テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物 |
KR102393596B1 (ko) | 2016-04-22 | 2022-05-04 | 리셉터 홀딩스, 인크. | 속효성 식물-계 의약 화합물 및 영양 보충제 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CN109414587A (zh) * | 2016-06-17 | 2019-03-01 | 强普生技股份有限公司 | 治疗肿瘤的方法 |
KR102606179B1 (ko) * | 2016-09-14 | 2023-11-28 | 아비박스 | 암의 치료를 위한 abx196을 포함하는 조합물 |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
US10398646B2 (en) | 2017-06-14 | 2019-09-03 | Crititech, Inc. | Methods for treating lung disorders |
TWI717629B (zh) * | 2017-08-28 | 2021-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cyp17抑制劑的藥物組合物及其製備方法 |
CN107475181B (zh) * | 2017-09-30 | 2021-03-02 | 中国农业大学 | 未成熟卵母细胞的体外成熟培养液及其应用 |
CN111278436A (zh) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
EA202090890A1 (ru) * | 2017-10-05 | 2020-09-03 | Ресептор Холдингз, Инк. | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия |
AU2018345812A1 (en) * | 2017-10-05 | 2020-05-14 | Spoke Sciences, Inc. | Herbal compositions with improved bioavailability |
CA3127584A1 (en) * | 2018-06-14 | 2019-12-19 | Metabolomycs, Inc. | Metabolomic signatures for predicting, diagnosing, and prognosing various diseases including cancer |
RU2704020C1 (ru) * | 2018-06-22 | 2019-10-23 | Общество с ограниченной ответственностью "ПеритонТрит" | Комбинация дегидроксиметилэпоксихиномицина (DHMEQ) и цитостатиков для лечения рака яичника |
US11439586B2 (en) | 2018-10-16 | 2022-09-13 | US Nano Food & Drug INC | Intratumour injection formulation |
EP4005583A4 (en) * | 2019-04-01 | 2023-04-26 | Industry - University Cooperation Foundation Hanyang University | ANTI-CANCER AGAINST PEPTIDE-BASED CP2C |
CA3169441A1 (en) | 2020-04-13 | 2021-10-21 | US Nano Food & Drug INC | Basic chemotherapeutic intratumour injection formulation |
CR20230308A (es) * | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
WO2022197743A1 (en) * | 2021-03-16 | 2022-09-22 | Multiple Energy Technologies Llc | Bioceramic compositions for cancer recovery |
US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE35748E (en) * | 1984-05-29 | 1998-03-17 | Matrix Pharmaceutical, Inc. | Treatments employing drug containing matrices for introduction into cellular lesion areas |
US4619913A (en) | 1984-05-29 | 1986-10-28 | Matrix Pharmaceuticals, Inc. | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
US4764381A (en) | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
US4983396A (en) | 1985-12-06 | 1991-01-08 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol |
US5118845A (en) | 1986-09-29 | 1992-06-02 | Whitby Research, Inc. | Penetration enhancer for transdermal delivery of systemic agents |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
US4978332A (en) * | 1987-09-28 | 1990-12-18 | Matrix Pharmaceutical, Inc. | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas |
US5162115A (en) * | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
US5219877A (en) | 1989-09-25 | 1993-06-15 | Bristol-Myers Squibb Company | Lauryl alcohol as skin penetration enhancer for topical imidazole agents |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
US6099856A (en) | 1992-06-15 | 2000-08-08 | Emisphere Technologies, Inc. | Active agent transport systems |
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
US6221367B1 (en) * | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
US5443841A (en) | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
WO1992020369A1 (en) * | 1991-05-14 | 1992-11-26 | Dana Farber Cancer Institute | Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents |
US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5693769A (en) | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US6916489B2 (en) | 1992-06-15 | 2005-07-12 | Emisphere Technologies, Inc. | Active agent transport systems |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5401516A (en) | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
EP1025840B1 (en) | 1993-04-22 | 2005-06-29 | Emisphere Technologies, Inc. | Oral drug compositions |
US20010003001A1 (en) | 1993-04-22 | 2001-06-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US5958457A (en) | 1993-04-22 | 1999-09-28 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US6461643B2 (en) | 1993-04-22 | 2002-10-08 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
US5965121A (en) | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
BR9604880A (pt) | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica |
US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6090958A (en) | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5989539A (en) | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5601839A (en) | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
US5820881A (en) | 1995-04-28 | 1998-10-13 | Emisphere Technologies, Inc. | Microspheres of diamide-dicarboxylic acids |
US6051258A (en) | 1995-06-07 | 2000-04-18 | Emisphere Technologies, Inc. | Proteinoid emulsions and methods for preparation and use thereof |
US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
EP0904074A4 (en) * | 1996-02-21 | 2006-01-11 | Intarcia Therapeutics Inc | USE OF CELL MEMBRANE THRUGHRINGS IN THE TREATMENT OF CELLULAR PROLIFERATIVE DISEASES |
SI9720025A (sl) | 1996-03-29 | 1999-08-31 | Emishphere Technologies, Inc. | Spojine in sestavki za prenos aktivne snovi |
AU2911197A (en) | 1996-05-24 | 1998-01-05 | Imperial College Of Science, Technology And Medicine | Polycationic sterol derivatives as transfection agents |
US5939381A (en) | 1997-02-07 | 1999-08-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5776888A (en) | 1997-02-07 | 1998-07-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6051561A (en) | 1997-02-07 | 2000-04-18 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6060513A (en) | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5876710A (en) | 1997-02-07 | 1999-03-02 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5804688A (en) | 1997-02-07 | 1998-09-08 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5990166A (en) | 1997-02-07 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
US5863944A (en) | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
JP4656675B2 (ja) | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | 脂質小胞への荷電した治療剤の高率封入 |
US6110492A (en) * | 1997-05-28 | 2000-08-29 | Jenner Biotherapies, Inc. | Immunogenic compositions |
DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
EP0998306A1 (en) | 1997-07-24 | 2000-05-10 | Inex Pharmaceuticals Corp. | Liposomal compositions for the delivery of nucleic acid catalysts |
US6225118B1 (en) | 1997-10-01 | 2001-05-01 | Biocure Limited | Multicellular in vitro assay of angiogenesis |
US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
JPH11246439A (ja) | 1998-03-02 | 1999-09-14 | Hisamitsu Pharmaceut Co Inc | 経粘膜用吸収促進剤 |
WO2000006184A1 (en) | 1998-07-27 | 2000-02-10 | Emisphere Technologies, Inc. | Pulmonary delivery of active agents |
US7648695B2 (en) | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
JP4430235B2 (ja) | 1998-08-07 | 2010-03-10 | エミスフェアー・テクノロジーズ・インク | 活性剤のデリバリーのための化合物及び組成物 |
US6991798B1 (en) | 1998-08-07 | 2006-01-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US7491796B1 (en) | 1998-11-19 | 2009-02-17 | Merrion Research Iii Limited | Retro-inversion peptides that target GIT receptors and related methods |
BR0008590A (pt) | 1999-01-08 | 2001-10-30 | Emisphere Tech Inc | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto |
US7084279B1 (en) | 1999-02-11 | 2006-08-01 | Emisphere Technologies Inc. | Oxadiazole compounds and compositions for delivering active agents |
US7479276B1 (en) | 1999-02-22 | 2009-01-20 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
WO2000050386A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
US20030181367A1 (en) | 1999-09-27 | 2003-09-25 | O'mahony Daniel | Conjugates of membrane translocating agents and pharmaceutically active agents |
US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
AU2274201A (en) | 1999-12-16 | 2001-06-25 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US7151191B2 (en) | 2000-01-13 | 2006-12-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
CA2402613A1 (en) | 2000-03-29 | 2001-10-04 | Igor Gonda | Cationic liposomes |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
DK1299348T3 (da) | 2000-06-29 | 2008-07-28 | Emisphere Tech Inc | Forbindelser og sammensætninger til levering af aktive midler |
JP4707931B2 (ja) | 2000-08-18 | 2011-06-22 | エミスフェアー・テクノロジーズ・インク | 活性剤デリバリー用化合物および組成物 |
JP4624642B2 (ja) | 2000-08-18 | 2011-02-02 | エミスフェアー・テクノロジーズ・インク | 活性剤デリバリー用化合物および組成物 |
WO2002019969A2 (en) | 2000-09-06 | 2002-03-14 | Emisphere Technologies Inc. | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
PT1317419E (pt) | 2000-09-06 | 2009-05-08 | Emisphere Tech Inc | Compostos e composições de ácido cianofenoxicarboxílico para administrar agentes activos |
US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
BRPI0115814B8 (pt) | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas |
EP2308479A3 (en) | 2001-03-01 | 2012-10-24 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
HUP0303616A3 (en) | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
AU2002256398A2 (en) | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
US20030176379A1 (en) | 2001-05-11 | 2003-09-18 | Raoof Araz A. | Antisense permeation enhancers |
CA2452056C (en) | 2001-07-02 | 2011-11-01 | Elan Corporation, Plc. | Compositions of bioactive material particles dispersed in a continuous solid encapsulating material |
JP4383855B2 (ja) | 2001-07-02 | 2009-12-16 | メリオン リサーチ スリー リミテッド | パイエル板および/またはm細胞を標的とするリガンド |
BR0103887C1 (pt) * | 2001-07-17 | 2005-11-08 | Univ Minas Gerais | Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes |
WO2003015698A2 (en) | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
WO2003045306A2 (en) | 2001-11-13 | 2003-06-05 | Emisphere Technologies, Inc. | Phenoxy amine compounds and compositions for delivering active agents |
EP1453546A2 (en) | 2001-12-04 | 2004-09-08 | Nanospectra Biosciences, Inc. | Treatment of angiogenesis disorders using targeted nanoparticles |
AU2002359892A1 (en) | 2001-12-31 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
WO2003059322A1 (en) | 2002-01-09 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
CA2471144C (en) | 2002-01-09 | 2011-06-07 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
WO2003083443A2 (en) | 2002-03-29 | 2003-10-09 | University Of Florida | Lipid mediated screening of drug candidates for identification of active compounds |
AU2003237686A1 (en) | 2002-05-24 | 2003-12-12 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
US20070071677A1 (en) * | 2003-03-10 | 2007-03-29 | Park Yoon J | Non-toxic membrane-translocating peptides |
WO2004081196A2 (en) * | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
WO2005089287A2 (en) | 2004-03-15 | 2005-09-29 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
WO2005115406A2 (en) | 2004-04-16 | 2005-12-08 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
EP1773351B1 (en) | 2004-05-06 | 2019-04-24 | Emisphere Technologies, Inc. | Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate |
ES2586423T3 (es) | 2004-05-14 | 2016-10-14 | Emisphere Technologies, Inc. | Compuestos de aril cetona y composiciones para administrar principios activos |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
WO2006085987A2 (en) | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
WO2006072070A2 (en) | 2004-12-29 | 2006-07-06 | Emisphere Technologies, Inc. | Pharmaceutical formulations of gallium salts |
US7820628B2 (en) | 2005-02-22 | 2010-10-26 | University Of Massachusetts Medical School | Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding |
US20070049557A1 (en) | 2005-08-24 | 2007-03-01 | Hashim Ahmed | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers |
BRPI0616558B1 (pt) | 2005-09-19 | 2021-09-08 | Emisphere Technologies, Inc | Forma i do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, forma ii do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, solvato de etanol cristalino do sal dissódico do ácido n-(5-salicioloil)-8-aminocaprílico, forma iii do sal dissódico do ácido n-(5-clorossaliciloil)-5- aminocapróico, octahidrato do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, composição farmacêutica, processo para preparar a forma i do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, processo para preparar um solvato de monoetanol do sal dissódico do ácido n-(5-saliciloil)-8-(...) |
JP2009519033A (ja) * | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
US20070196277A1 (en) | 2006-01-20 | 2007-08-23 | Levin Victor A | Compositions and Methods for the Direct Therapy of Tumors |
CA2676841C (en) * | 2007-01-31 | 2017-09-26 | Rutgers, The State University Of New Jersey | Controlled release of actives in skin |
EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
US20090275654A1 (en) | 2008-04-30 | 2009-11-05 | Genta Incorporated | Pharmaceutical Gallium Compositions and Methods |
AU2009260485B2 (en) * | 2008-05-30 | 2015-01-29 | Novelix Pharmaceuticals, Inc. | Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
BRPI1005919B1 (pt) * | 2009-02-27 | 2021-06-22 | Toray Industries, Inc | Composição imunogênica |
WO2011084061A1 (en) * | 2010-01-08 | 2011-07-14 | Universitair Medisch Centrum St. Radboud | Cpp (cell penetrating peptide) and its uses |
CN101928234B (zh) | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-(杂)芳基-n-羟基己/庚酰胺化合物及其制备方法 |
WO2011112889A2 (en) * | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY |
MX350927B (es) | 2010-08-26 | 2017-09-26 | Toray Ind Inc Star | Composicion inmunogenica. |
WO2014018932A2 (en) | 2012-07-27 | 2014-01-30 | Bunt Antonius Martinus Gustave | Effluz inhibitor compositions and methods of treatment using the same |
DK2897620T3 (da) | 2012-09-21 | 2020-08-17 | Intensity Therapeutics Inc | Fremgangsmåde til behandling af cancer |
-
2013
- 2013-09-15 DK DK13838639.6T patent/DK2897620T3/da active
- 2013-09-15 SG SG10202011046RA patent/SG10202011046RA/en unknown
- 2013-09-15 CN CN201380059949.2A patent/CN104884065B/zh active Active
- 2013-09-15 KR KR1020157010173A patent/KR101839864B1/ko active IP Right Grant
- 2013-09-15 CA CA2884707A patent/CA2884707C/en active Active
- 2013-09-15 EP EP13838639.6A patent/EP2897620B1/en active Active
- 2013-09-15 RU RU2015114767A patent/RU2657749C2/ru active
- 2013-09-15 SG SG11201501850VA patent/SG11201501850VA/en unknown
- 2013-09-15 WO PCT/US2013/059841 patent/WO2014046983A1/en active Application Filing
- 2013-09-15 BR BR112015006176-1A patent/BR112015006176B1/pt active IP Right Grant
- 2013-09-15 ES ES13838639T patent/ES2813340T3/es active Active
- 2013-09-15 AU AU2013318338A patent/AU2013318338B2/en active Active
- 2013-09-15 MX MX2015003643A patent/MX2015003643A/es active IP Right Grant
- 2013-09-15 JP JP2015533122A patent/JP6374388B2/ja active Active
- 2013-09-15 PL PL13838639T patent/PL2897620T3/pl unknown
- 2013-09-15 PT PT138386396T patent/PT2897620T/pt unknown
-
2014
- 2014-05-16 US US14/280,036 patent/US9351997B2/en active Active
-
2015
- 2015-03-16 IL IL237791A patent/IL237791B/en active IP Right Grant
- 2015-03-19 CL CL2015000699A patent/CL2015000699A1/es unknown
-
2016
- 2016-02-24 US US15/052,326 patent/US9636406B2/en active Active
-
2017
- 2017-02-24 US US15/441,907 patent/US10888618B2/en active Active
- 2017-05-04 AU AU2017202970A patent/AU2017202970B2/en active Active
-
2018
- 2018-03-06 JP JP2018039402A patent/JP2018123137A/ja active Pending
-
2020
- 2020-08-12 CY CY20201100752T patent/CY1123258T1/el unknown
- 2020-12-01 US US17/108,099 patent/US20210077627A1/en not_active Abandoned
-
2023
- 2023-06-16 US US18/336,379 patent/US20230338251A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
CL2016000354A1 (es) | Modulación de la inmunidad tumoral | |
GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
CL2015002807A1 (es) | Terapia de combinación | |
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
CL2016000378A1 (es) | Composiciones y métodos terapéuticos para la regresión acelerada de placa | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
NI201500151A (es) | Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata. | |
CL2016000379A1 (es) | Composiciones y métodos terapéuticos para reducción acelerada de plagas | |
PE20150020A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides | |
MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
EA201690445A1 (ru) | Лечение рака | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
CR20140480A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek |